The Current Pathogenicity and Potential Risk Evaluation of Marburg Virus to Cause Mysterious "Disease X"-An Update on Recent Evidences
Environ Health Insights. 2024 Mar 4;18:11786302241235809. doi: 10.1177/11786302241235809. eCollection 2024.ABSTRACTThe World Health Organization (WHO) defined Disease X as an upcoming disease with the potential to cause a pandemic. Pathogen X is responsible for Disease X. Marburg virus disease (MVD) is one of the diseases from the priority disease list published by WHO. Marburg virus is a filamentous, negative-sense RNA virus that belongs to the same filovirus family as the lethal Ebola virus. Since the first discovery of this virus in 1967, 17 outbreaks occurred sporadically till 2023. Rousettus aegyptiacus acts as the na...
Source: Environmental Health Insights - March 5, 2024 Category: Environmental Health Authors: Rahima Akter Mitu Md Rabiul Islam Source Type: research
Transcriptomics of Marburg virus-infected primary proximal tubular cells reveals negative correlation of immune response and energy metabolism
In conclusion, Marburg virus infects and replicates in human primary PTC and induces downregulation of processes known to be relevant for acute kidney injury as well as a strong inflammatory response.PMID:38346476 | DOI:10.1016/j.virusres.2024.199337 (Source: Virus Research)
Source: Virus Research - February 12, 2024 Category: Virology Authors: Benjamin Koch Maximilian Filzmayer Sammy Patyna Nils Wetzstein Sebastian Lampe Tobias Schmid Helmut Geiger Patrick C Baer Olga Dolnik Source Type: research
Recent Advancements in the Therapeutic Development for Marburg Virus: Updates on Clinical Trials
AbstractPurpose of ReviewWe aim to provide valuable insights into the current state of therapeutic development for the deadly Marburg virus and guide researchers and clinicians to study the emerging therapies and shape future directions against this deadly virus.Recent FindingsWe find considerable progress in understanding the molecular biology and pathogenesis of the Marburg virus, leading to the identification of small-molecule antivirals and host-targeted approaches, including RNA polymerase inhibitors, viral entry inhibitors, and RNA interference therapies. However, there are very few ongoing clinical trials on the the...
Source: Current Infectious Disease Reports - February 1, 2024 Category: Infectious Diseases Source Type: research
Prophylactic and therapeutic measures for emerging and re-emerging viruses: artificial intelligence and machine learning - the key to a promising future
ConclusionsThe present review not only highlighted public-health management models but also provide leads in potential therapeutic targets as well as vaccine/ antiviral candidates. To support the context, the issues with existing therapeutic strategies are also overviewed and the prospects were identified. This review discusses a wide range of applications of AI and ML pertaining to the clinical domain. (Source: Health and Technology)
Source: Health and Technology - January 24, 2024 Category: Information Technology Source Type: research
Recent Advancements in the Therapeutic Development for Marburg Virus: Updates on Clinical Trials
AbstractPurpose of ReviewWe aim to provide valuable insights into the current state of therapeutic development for the deadly Marburg virus and guide researchers and clinicians to study the emerging therapies and shape future directions against this deadly virus.Recent FindingsWe find considerable progress in understanding the molecular biology and pathogenesis of the Marburg virus, leading to the identification of small-molecule antivirals and host-targeted approaches, including RNA polymerase inhibitors, viral entry inhibitors, and RNA interference therapies. However, there are very few ongoing clinical trials on the the...
Source: Current Infectious Disease Reports - January 15, 2024 Category: Infectious Diseases Source Type: research
Peripheral immune responses to filoviruses in a reservoir versus spillover hosts reveal transcriptional correlates of disease
Several filoviruses, including Marburg virus (MARV), cause severe disease in humans and nonhuman primates (NHPs). However, the Egyptian rousette bat (ERB, Rousettus aegyptiacus), the only known MARV reservoir, shows no overt illness upon natural or experimental infection, which, like other bat hosts of zoonoses, is due to well-adapted, likely species-specific immune features. Despite advances in understanding reservoir immune responses to filoviruses, ERB peripheral blood responses to MARV and how they compare to those of diseased filovirus-infected spillover hosts remain ill-defined. We thus conducted a longitudinal analy...
Source: Frontiers in Immunology - January 8, 2024 Category: Allergy & Immunology Source Type: research
Markers of antroponotic viral infections in vervet monkeys arrived from their natural habitat (Tanzania)
CONCLUSION: When importing monkeys from different regions of the world, an expanded screening for viral infections is needed considering the epidemiological situation both in the country of importation and in the country of destination.PMID:38156576 | DOI:10.36233/0507-4088-188 (Source: Herpes)
Source: Herpes - December 29, 2023 Category: Infectious Diseases Authors: D I Dogadov K K Kyuregyan G M Alexandra A A Minosyan A A Kochkonyan A A Karlsen O I Vyshemirsky D D Karal-Ogly M I Mikhailov Source Type: research
Markers of antroponotic viral infections in vervet monkeys arrived from their natural habitat (Tanzania)
CONCLUSION: When importing monkeys from different regions of the world, an expanded screening for viral infections is needed considering the epidemiological situation both in the country of importation and in the country of destination.PMID:38156576 | DOI:10.36233/0507-4088-188 (Source: Herpes)
Source: Herpes - December 29, 2023 Category: Infectious Diseases Authors: D I Dogadov K K Kyuregyan G M Alexandra A A Minosyan A A Kochkonyan A A Karlsen O I Vyshemirsky D D Karal-Ogly M I Mikhailov Source Type: research
Markers of antroponotic viral infections in vervet monkeys arrived from their natural habitat (Tanzania)
CONCLUSION: When importing monkeys from different regions of the world, an expanded screening for viral infections is needed considering the epidemiological situation both in the country of importation and in the country of destination.PMID:38156576 | DOI:10.36233/0507-4088-188 (Source: Herpes)
Source: Herpes - December 29, 2023 Category: Infectious Diseases Authors: D I Dogadov K K Kyuregyan G M Alexandra A A Minosyan A A Kochkonyan A A Karlsen O I Vyshemirsky D D Karal-Ogly M I Mikhailov Source Type: research
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
Vaccine. 2023 Dec 28:S0264-410X(23)01499-8. doi: 10.1016/j.vaccine.2023.12.053. Online ahead of print.ABSTRACTAlthough two vaccines for Zaire ebolavirus (EBOV) have been licensed and deployed successfully to combat recurring outbreaks of Ebolavirus Disease in West Africa, there are no vaccines for two other highly pathogenic members of the Filoviridae, Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV). The results described herein document the immunogenicity and protective efficacy in cynomolgus macaques of a single-vial, thermostabilized (lyophilized) monovalent (SUDV) and bivalent (SUDV & MARV) protein vaccines...
Source: Vaccine - December 29, 2023 Category: Allergy & Immunology Authors: Albert To Teri Ann S Wong Aquena H Ball Michael M Lieberman Jake Yalley-Ogunro Mehtap Cabus Sara Nezami Fabian Paz Hanne Andersen Elyard Viktoriya Borisevich Krystle N Agans Daniel J Deer Courtney Woolsey Robert W Cross Thomas W Geisbert Oreola Donini Axe Source Type: research
Markers of antroponotic viral infections in vervet monkeys arrived from their natural habitat (Tanzania)
CONCLUSION: When importing monkeys from different regions of the world, an expanded screening for viral infections is needed considering the epidemiological situation both in the country of importation and in the country of destination.PMID:38156576 | DOI:10.36233/0507-4088-188 (Source: Herpes)
Source: Herpes - December 29, 2023 Category: Infectious Diseases Authors: D I Dogadov K K Kyuregyan G M Alexandra A A Minosyan A A Kochkonyan A A Karlsen O I Vyshemirsky D D Karal-Ogly M I Mikhailov Source Type: research
Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomised controlled trial
CONCLUSIONS: In this study, adjuvant IA did not show a shorter time to clinical remission but a corticosteroid-sparing effect. In patients with extensive PV/PF, post hoc analysis suggests that adjuvant IA may possibly lead to earlier remission, but potential adverse events must be carefully weighed against the expected benefits.PMID:38133541 | DOI:10.1093/bjd/ljad489 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - December 22, 2023 Category: Dermatology Authors: Nina van Beek R üdiger Eming Alexander Reuss Detlef Zillikens Mikl ós Sárdy Claudia G ünther Dimitra Kiritsi Sandrine Benoit Stefan Beissert Regine Gl äser Harald Gollnick Orsolya N Horv áth Christiane Pfeiffer Martin R öcken Franziska Schauer Step Source Type: research
Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomised controlled trial
CONCLUSIONS: In this study, adjuvant IA did not show a shorter time to clinical remission but a corticosteroid-sparing effect. In patients with extensive PV/PF, post hoc analysis suggests that adjuvant IA may possibly lead to earlier remission, but potential adverse events must be carefully weighed against the expected benefits.PMID:38133541 | DOI:10.1093/bjd/ljad489 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - December 22, 2023 Category: Dermatology Authors: Nina van Beek R üdiger Eming Alexander Reuss Detlef Zillikens Mikl ós Sárdy Claudia G ünther Dimitra Kiritsi Sandrine Benoit Stefan Beissert Regine Gl äser Harald Gollnick Orsolya N Horv áth Christiane Pfeiffer Martin R öcken Franziska Schauer Step Source Type: research
Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomised controlled trial
CONCLUSIONS: In this study, adjuvant IA did not show a shorter time to clinical remission but a corticosteroid-sparing effect. In patients with extensive PV/PF, post hoc analysis suggests that adjuvant IA may possibly lead to earlier remission, but potential adverse events must be carefully weighed against the expected benefits.PMID:38133541 | DOI:10.1093/bjd/ljad489 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - December 22, 2023 Category: Dermatology Authors: Nina van Beek R üdiger Eming Alexander Reuss Detlef Zillikens Mikl ós Sárdy Claudia G ünther Dimitra Kiritsi Sandrine Benoit Stefan Beissert Regine Gl äser Harald Gollnick Orsolya N Horv áth Christiane Pfeiffer Martin R öcken Franziska Schauer Step Source Type: research
